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 Myasthenia Gravis is an autoimmune disorder in which antibodies attack the nicotinic 
acetylcholine postsynaptic receptors at the neuromuscular junction in skeletal muscle. The 
muscle cannot respond to the nerve impulses, resulting in voluntary skeletal muscle weakness. 
There is currently no cure for Myasthenia Gravis. It is possible that other types of receptors are 
expressed in skeletal muscle, which could be targeted to increase synaptic transmission without 
the use of acetylcholine. A study was performed to test whether embryonic zebrafish skeletal 
muscle expresses non-cholinergic receptors. Zebrafish embryos, ages 16 hours post fertilization 
to 7 days post fertilization, were incubated in primary antibody in goat serum. This included 
AMPA, NMDA, IgG, or no primary as a control. Embryos were then incubated in fluorescent 
secondary antibodies. The embryo tails were dissected and mounted on slides for imaging. The 
area of receptor expression was analyzed using intensity thresholding in ImageJ software. We 
found that zebrafish skeletal muscle expresses NMDA receptors. These receptors may be useful 
as an alternate route for treatment of diseases, like Myasthenia Gravis.  
 
